Tags

Type your tag names separated by a space and hit enter

Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.
Curr Hematol Malig Rep 2012; 7(3):235-40CH

Abstract

Peripheral T-cell lymphoma (PTCL) is a group of lymphoid malignancy that remains difficult to treat, as most PTCL becomes refractory or relapses, and thus there is an unmet medical need for novel treatment modalities. CC chemokine receptor 4 (CCR4) is expressed in various types of PTCL including adult T-cell leukemia-lymphoma (ATL), which has the worst prognosis among them. A phase II study of a defucosylated, humanized anti-CCR4 monoclonal antibody, mogamulizumab (KW-0761), yielded an overall response rate of 50 % (13/26) and a median progression-free survival of 5.2 months in relapsed patients with CCR4-positive ATL who had been previously treated with chemotherapy. Mogamulizumab also showed potential efficacy for cutaneous T-cell lymphoma in a US phase I/II study. Further preclinical and clinical investigations are needed to examine whether concomitant use of this novel agent with other agents with different mechanisms of action would be more effective for ATL and other PTCLs.

Authors+Show Affiliations

Department of Hematology, and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan. ktobinai@ncc.go.jpNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

22538464

Citation

Tobinai, Kensei, et al. "Targeting Chemokine Receptor CCR4 in Adult T-cell Leukemia-lymphoma and Other T-cell Lymphomas." Current Hematologic Malignancy Reports, vol. 7, no. 3, 2012, pp. 235-40.
Tobinai K, Takahashi T, Akinaga S. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Curr Hematol Malig Rep. 2012;7(3):235-40.
Tobinai, K., Takahashi, T., & Akinaga, S. (2012). Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. Current Hematologic Malignancy Reports, 7(3), pp. 235-40. doi:10.1007/s11899-012-0124-3.
Tobinai K, Takahashi T, Akinaga S. Targeting Chemokine Receptor CCR4 in Adult T-cell Leukemia-lymphoma and Other T-cell Lymphomas. Curr Hematol Malig Rep. 2012;7(3):235-40. PubMed PMID: 22538464.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas. AU - Tobinai,Kensei, AU - Takahashi,Takeshi, AU - Akinaga,Shiro, PY - 2012/4/28/entrez PY - 2012/4/28/pubmed PY - 2012/12/19/medline SP - 235 EP - 40 JF - Current hematologic malignancy reports JO - Curr Hematol Malig Rep VL - 7 IS - 3 N2 - Peripheral T-cell lymphoma (PTCL) is a group of lymphoid malignancy that remains difficult to treat, as most PTCL becomes refractory or relapses, and thus there is an unmet medical need for novel treatment modalities. CC chemokine receptor 4 (CCR4) is expressed in various types of PTCL including adult T-cell leukemia-lymphoma (ATL), which has the worst prognosis among them. A phase II study of a defucosylated, humanized anti-CCR4 monoclonal antibody, mogamulizumab (KW-0761), yielded an overall response rate of 50 % (13/26) and a median progression-free survival of 5.2 months in relapsed patients with CCR4-positive ATL who had been previously treated with chemotherapy. Mogamulizumab also showed potential efficacy for cutaneous T-cell lymphoma in a US phase I/II study. Further preclinical and clinical investigations are needed to examine whether concomitant use of this novel agent with other agents with different mechanisms of action would be more effective for ATL and other PTCLs. SN - 1558-822X UR - https://www.unboundmedicine.com/medline/citation/22538464/Targeting_chemokine_receptor_CCR4_in_adult_T_cell_leukemia_lymphoma_and_other_T_cell_lymphomas_ L2 - https://dx.doi.org/10.1007/s11899-012-0124-3 DB - PRIME DP - Unbound Medicine ER -